Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

BACKGROUND: Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung cancer. We report an analysis of the STARTRK-NG trial, investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Ami V, Robinson, Giles W, Gauvain, Karen, Basu, Ellen M, Macy, Margaret E, Maese, Luke, Whipple, Nicholas S, Sabnis, Amit J, Foster, Jennifer H, Shusterman, Suzanne, Yoon, Janet, Weiss, Brian D, Abdelbaki, Mohamed S, Armstrong, Amy E, Cash, Thomas, Pratilas, Christine A, Corradini, Nadège, Marshall, Lynley V, Farid-Kapadia, Mufiza, Chohan, Saibah, Devlin, Clare, Meneses-Lorente, Georgina, Cardenas, Alison, Hutchinson, Katherine E, Bergthold, Guillaume, Caron, Hubert, Chow Maneval, Edna, Gajjar, Amar, Fox, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Pediatric Neuro-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527518/
https://www.ncbi.nlm.nih.gov/pubmed/35395680
http://dx.doi.org/10.1093/neuonc/noac087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527518/
https://www.ncbi.nlm.nih.gov/pubmed/35395680
http://dx.doi.org/10.1093/neuonc/noac087

Ejemplares similares